A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
- PMID: 29698934
- PMCID: PMC5918142
- DOI: 10.1016/j.tranon.2018.03.014
A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis
Abstract
The first tenet of medicine, "primum non nocere" or "first, do no harm", is not always compatible with oncological interventions e.g., chemotherapy, targeted therapy and radiation, since they commonly result in significant toxicities. One of the more frequent and serious treatment-induced toxicities is mucositis and particularly oral mucositis (OM) described as inflammation, atrophy and breakdown of the mucosa or lining of the oral cavity. The sequelae of oral mucositis (OM), which include pain, odynodysphagia, dysgeusia, decreased oral intake and systemic infection, frequently require treatment delays, interruptions and discontinuations that not only negatively impact quality of life but also tumor control and survivorship. One potential strategy to reduce or prevent the development of mucositis, for which no effective therapies exist only best supportive empirical care measures, is the administration of agents referred to as radioprotectors and/or chemoprotectors, which are intended to differentially protect normal but not malignant tissue from cytotoxicity. This limited-scope review briefly summarizes the incidence, pathogenesis, symptoms and impact on patients of OM as well as the background and mechanisms of four clinical stage radioprotectors/chemoprotectors, amifostine, palifermin, GC4419 and RRx-001, with the proven or theoretical potential to minimize the development of mucositis particularly in the treatment of head and neck cancers.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Figures






Similar articles
-
Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.Drugs Today (Barc). 2007 Jul;43(7):461-73. doi: 10.1358/dot.2007.43.7.1119723. Drugs Today (Barc). 2007. PMID: 17728847 Review.
-
Diagnosis and management of oral mucositis.J Support Oncol. 2007 Feb;5(2 Suppl 1):13-21. J Support Oncol. 2007. PMID: 17366929 Review.
-
New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies.Am J Health Syst Pharm. 2012 Jun 15;69(12):1031-7. doi: 10.2146/ajhp100531. Am J Health Syst Pharm. 2012. PMID: 22644979 Review.
-
Pharmacological modulation of radiation-induced oral mucosal complications.Cancer Radiother. 2018 Sep;22(5):429-437. doi: 10.1016/j.canrad.2017.11.006. Epub 2018 May 26. Cancer Radiother. 2018. PMID: 29776830 Review.
-
Mucositis: current management and investigations.Semin Radiat Oncol. 2003 Jul;13(3):267-73. doi: 10.1016/S1053-4296(03)00028-6. Semin Radiat Oncol. 2003. PMID: 12903015
Cited by
-
Milk modulates macrophage polarization in vitro.Cytokine X. 2019 May 25;1(2):100009. doi: 10.1016/j.cytox.2019.100009. eCollection 2019 Jun. Cytokine X. 2019. PMID: 33604549 Free PMC article.
-
Uses of Natural Honey in Cancer: An Updated Review.Adv Pharm Bull. 2022 Mar;12(2):248-261. doi: 10.34172/apb.2022.026. Epub 2021 Feb 1. Adv Pharm Bull. 2022. PMID: 35620330 Free PMC article. Review.
-
The Effectiveness of Curcumin in Treating Oral Mucositis Related to Radiation and Chemotherapy: A Systematic Review.Antioxidants (Basel). 2024 Sep 25;13(10):1160. doi: 10.3390/antiox13101160. Antioxidants (Basel). 2024. PMID: 39456414 Free PMC article. Review.
-
A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment.Support Care Cancer. 2021 Sep;29(9):4939-4947. doi: 10.1007/s00520-021-06108-w. Epub 2021 Mar 13. Support Care Cancer. 2021. PMID: 33712912 Free PMC article. Review.
-
Natural Products for the Prevention and Treatment of Oral Mucositis-A Review.Int J Mol Sci. 2022 Apr 15;23(8):4385. doi: 10.3390/ijms23084385. Int J Mol Sci. 2022. PMID: 35457202 Free PMC article. Review.
References
-
- Chaveli López B, Gavaldá Esteve C, Sarrión Pérez MG. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2011;3:e31–42.
-
- Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009;4(2):135–142. - PubMed
-
- Alterio D, Jereczek-Fossa BA, Fiore MR, Piperno G, Ansarin M, Orecchia R. Cancer treatment-induced oral mucositis. Anticancer Res. 2007;27(2):1105–1125. - PubMed
-
- McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993;20:1493–1502. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources